CONTERA PHARMA A/S: Financial statements 2017
CVR: 33062214
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 1,418,538 and a net result of DKK -418,534 compared with DKK 866,364 the year before. That is a decrease of 54.4% compared with the year before. Equity in the 2017 report amounted to DKK 1,048,360. The solvency ratio was 73.7%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 1,418,538
- Profit/Loss
- DKK -418,534
- Equity
- DKK 1,048,360
- Total Assets
- DKK 1,422,930
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | 1.4 mio. | -419 t. | 1 mio. | 2 |
| 2016 | - | 3.1 mio. | 866 t. | 1.5 mio. | - |
| 2015 | - | 445 t. | -1.1 mio. | 601 t. | - |
| 2014 | - | -126 t. | -3.2 mio. | 1.7 mio. | - |
| 2013 | - | -3.4 mio. | -4.7 mio. | 1.7 mio. | - |
Official annual report
Keep an eye on CONTERA PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
CONTERA PHARMA A/S has published its annual report for 2016. Gross profit came to DKK 3,107,817, and the net result was DKK 866,364.
About CONTERA PHARMA A/S
CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The board consists of Jae Young Lee (chair), Jee Hun Kim, Paul Ejnar Gremaud Kristjansen and Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity in the 2025 report amounted to DKK 79,471,802.